The following is a summary of “Factors predicting local or systemic side effects related to intravesical BCG (Bacillus ...
Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results